Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. - Wikidata - wikimedia - TriplyDB

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

http://www.wikidata.org/entity/Q34179527

about

Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses Vaccines against invasive Salmonella disease: current status and future directions Delivering vaccines to the people who need them most Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis.Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB Glycoconjugate vaccine strategies for protection against invasive Salmonella infections.The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.Typhoid fever & vaccine development: a partially answered question.Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development.[New aspects in travel vaccinations].A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.O-Serotype Conversion in Salmonella Typhimurium Induces Protective Immune Responses against Invasive Non-Typhoidal Salmonella Infections.The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.Structural and immunological characterization of derived recombinant CRM protein used as carrier in conjugate vaccines

P2860

Q26746887-B36916F9-8BA9-4F02-80FA-03466F1F0099 Q27007088-903812ED-D5B4-4B09-93ED-8336E983D1BF Q28082744-0F269CF7-CDD2-4924-B929-10459F2407DD Q28744376-0FBC073F-58C7-47CC-B479-4F8CEF86CA5C Q34739155-CB1BD268-01EC-4294-9C35-905BE7B00B11 Q35272921-01E39634-A923-42DD-837E-3AA0583AA3ED Q35924773-34A09641-4FF2-4E1A-AD29-9B61FC1951DA Q36184367-11CE6C05-547D-4ABC-9BA7-77D1D1DE3511 Q36708987-62DABEA8-0246-4162-B660-A04FC92F5312 Q37340441-9DBB62D3-CDA6-4C7F-9A3B-D34B523E3E17 Q37996843-0863BAAF-60D3-4487-A147-100D9C7EAAB3 Q38140038-0649011E-FC2E-4311-812D-E619364DF5FA Q40203647-1A6A461E-6243-48C2-A610-B4B144A3F9BE Q40291567-ED1595A1-F02D-4A2B-B288-FC2D2E3AF919 Q47103827-D03F3D23-F15F-4A7B-94B2-1C22B8993894 Q47245287-5008B7E4-4387-4957-BAB2-602C380B850F Q58699527-BE6192B1-FD95-4DB8-9367-0013BCB9968A

P2860

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

http://www.wikidata.org/entity/Q34179527

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@ast

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@en

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@nl

type

label

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@ast

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@en

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@nl

prefLabel

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@ast

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@en

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@nl

P1433

Q34179527-C5592911-6832-4418-BFEF-E1093F6E4C2B

P1476

Q34179527-CA80D936-41C5-4777-8FA6-4487C2D972BD

P2093

Q34179527-067E4D27-E268-4DE1-BAB6-0F4DACC08EF7

Q34179527-0ED0E39D-8BB0-451E-9266-C454649D0CAA

Q34179527-181DF803-5D77-48AF-9A42-B11FF81A0378

Q34179527-3983BFED-C864-4250-83EF-61E2425736CA

Q34179527-569A5725-890E-452A-B84B-C2E9FE606069

Q34179527-624DF614-3605-4C17-9541-F0065FD9AA16

Q34179527-88A719CF-EF51-4900-89CC-728A3486B347

Q34179527-9B57A1E9-020A-4896-A4A1-D362BCE743DA

Q34179527-D8707B86-23DE-426B-A404-85B1E6F89706

Q34179527-E77E1409-915B-4DDF-A5FD-6C0B6476339A

P2860

Q34179527-00B5063C-4210-498C-BEEE-9B7A793E1327

Q34179527-092EB8E3-F2E0-4D01-BD0C-D6AE1B8A788B

Q34179527-0E624D2A-2836-432D-AAD2-33C3ABB36A82

Q34179527-1777BF20-7627-4DF0-89FD-F2575DF369E8

Q34179527-17D0C1E2-5F54-4BAD-ACD2-3D5B6B36FF80

Q34179527-1AA3C544-1ECB-48D2-8782-03FB80CA9B60

Q34179527-1C0AF240-78E1-40CE-B6FB-87FB992F7391

Q34179527-20F01B03-7712-49B0-94C9-E8BD2857EF46

Q34179527-29A767A7-BE4A-4F1E-A0F2-37DAA9522604

Q34179527-30ABE5C9-5775-47C5-8AA0-B993C4448418

P304

Q34179527-1C458203-19E4-46D0-8B07-88E499005A32

P31

Q34179527-9FD075C5-65F9-4034-BD4B-021F351D8080

P356

Q34179527-E1E53D58-7292-4994-8B6B-D8AB946A9590

P407

Q34179527-AD526AB7-479A-44F0-8AA8-225520614FC4

P433

Q34179527-B742AFE8-EAB3-4B60-8466-109197243CC6

P478

Q34179527-65684BEC-2C7C-4D8C-9B62-AE9188BADC00

P577

Q34179527-D0192862-5284-4542-B34E-D5EFBA5A4DD3

P698

Q34179527-B1D9BED1-8D4F-496A-B6EE-878B54458395

P932

Q34179527-AE0FC0CD-0007-41D2-BFA7-90330FB78870

P356

J.VACCINE.2010.11.022

P1433

P1476

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

@en

P2093

A Saul

http://www.w3.org/2001/XMLSchema#string

D Proietti

http://www.w3.org/2001/XMLSchema#string

F Berti

http://www.w3.org/2001/XMLSchema#string

F Micoli

http://www.w3.org/2001/XMLSchema#string

I Pisoni

http://www.w3.org/2001/XMLSchema#string

L B Martin

http://www.w3.org/2001/XMLSchema#string

P Costantino

http://www.w3.org/2001/XMLSchema#string

R Rappuoli

http://www.w3.org/2001/XMLSchema#string

S Rondini

http://www.w3.org/2001/XMLSchema#string

S Szu

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccines for preventing typhoid fever

The global burden of typhoid fever

Development of a new method for the quantitative analysis of the extracellular polysaccharide of Neisseria meningitidis serogroup A by use of high-performance anion-exchange chromatography with pulsed-amperometric detection.

Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.

Bacterial polysaccharide-protein conjugate vaccines.

The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines.

Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.

Carbohydrate-protein conjugate vaccines.

P304

712-720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2010.11.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21115057

http://www.w3.org/2001/XMLSchema#string

P932

4163788

http://www.w3.org/2001/XMLSchema#string